We would love to hear your thoughts about our site and services, please take our survey here.
When you first invested they only had CDX and HuPHEC both of which were pre clinical.... Soon.... yea there's that.
A reminder that Hemogenyx ARE clinical, a feat which was achieved on minimal budget, clinical trials will start as soon as a hospital has approved the protocol which could be days/weeks/months and the first patient is identified. Any speculation on exactly when that will be is pure speculation that includes from Hemogenyx.
Along side this they have a potential game changer with a nasal spray to deliver CBR that can treat viruses, cancer and degenerative diseases.
To say Hemo is undervalued is an understatement, however moaning about that fact is going to achieve even less than not moaning about it. Larger investors and companies wont rely on LSE for their research, but smaller PIs and traders WILL. Feel free to create a negative hostile environment, or maybe once in a while focus on the positives. Remember, most funds, who you WANT to invest here wont touch any company with a barge pole below a 50m mCap. That is not so big a reach with positivity and decent return of buyers. The chart has bottomed out with volume all but gone, seen by many traders as a good time to buy "for a trade" not welcomed or what we want, but if it helps restore the mCap back towards that 50 mark and we can start catching the eyes of some grown ups so be it!
Shicky, from what I understand Eli did not at that time want to pursue oncology, it was not on their roadmap and whilst they had fantastic early interest in CDX for many years the company moved in a different direction which meant that CDX was not going to progress very fast if Hemo waited for them. Instead they licenced all of the IP created and necessary for Hemogenyx to progress or sell CDX meaning that Hemo could look for new suitors OR progress themselves. I dont believe it had anything to do with money or valuations or even believe in the product, it just did not fit into Eli's strategic plans.
In terms of where CDX goes next, it is a new treatment which means the FDA are likely to have a long list of requirements before approving an IND, I THINK this is the main reason Hemo have not made much movement here in house, I expect the level of testing and checks demanded is going to cost alot of money which the company just cannot afford.
Which leaves them having to partner/licence/JV etc to progress, something which if they do now PRE clinical with CDX is going to attract a much lower premium, catch 22, sell it now cheap and prove it works but then you have already sold... or cant prove it works until you sell to raise enough money... Vlad has been saying for well over a year now that they are in licencing talks and you must imagine this is the issue, Vlad wont sell too cheap, and the pharma wont want to pay until they know it works!
HOWEVER.... What is important to remember is that BOTH HEMO-CAR-T and CDX are dependant on this patent:
"MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN" - Basically if the current HEMO-CAR-T trials go well and validate the efficiency of the receptor chosen then there will be some validation of CDX as a by-product. Basically HEMO-CAR-T AND CDX are likely hinging on the success of these upcoming trials.
If CAR-T works then CDX is a much simpler construct, OTS and cheaper, potential to be a major disruptor to chemotherapy and much more likely to be available though Medicare and Medicaid. It will have a massive list of off label applications and should be worth billions. BUT HEMO-CAR-T is targeting a tiny patient pool with an urgent need with a proven technology that is cheaper and much faster to get FDA approval.
TL;DR Version - CDX is very much in the pipeline, but its fate is bound to HEMO-CAR-T as both use https://patents.google.com/patent/US11104738B2/en
What's funny is the people moaning today will do a 180 and be full blown bulls when it's blue and FOMO kicks in. IF today was the end of the sub placing flips then tomorrow is blue and they will have wasted all this energy being grumpy.
Why? Err because the FCA suspended my brokers licence and I didn't register anywhere else. And yes my broker was referred by peterhouse and used jarvis. I have forms to register with new broker at home, but I have been busy.
They wanted funds, they did not want to sell or license, it is not any more complicated than that. Easy to raise money if you give away your lead candidate for peanuts, vlad did not do that. As for prevail? Ask them?
False I got no sounding, that said the sounding had minimal impact until they opened up to peterhouse.
Anyway it's done, VLAD PLEASE LEARN THE LESSON, DO NOT DO PLACINGS WITH PETERHOUSE. Company are funded, those big trades look like they could be the end of whatever block they were handling, they are Clinical and next step is Clinical trials. People can be upset and grumpy, but odds look good for start of recovery tomorrow.
Indeed, banked huge profit, did fair bit of reputational damage, made it harder for the company to raise a useful amount. Well done them!
Tell us again pumpkin how people don't short hemo and traders make no difference:p
The 12.5 is a sell, 12.1m is a buy, ig closing cfds and spreads, consolidation trade.
Pumpkin, as per my other post, its impossible to know, some will have been sold days or weeks in advance and will never print. Others will be sold at a loss (but probably not really a loss more of a tax fiddle), but others will hold. I was not in this placing but I was in the 1.5p placing to get rid of the CLNs. Thats a few million shares that were in my account then and are still in my account today, you dont HAVE to sell, just many flippers chose to do so.
If you look at the volumes of borrowed stock on IB after CH lift + add the 400m+ total volume since the placing was actually done think you might find we are not that far away. OR maybe ALOT of LTHers got fed up and dumped and that is skewing the numbers? Who knows.
An authorised broker can forward sell shares on behalf of an individual as long as the actual shares are available to settle within X days (variable). I have done it with other shares, perfectly legal and above board, once I got quite a big allocation in BIDS and was able to forward sell most, clear the entire fee, keep some for a free ride AND got warrants to boot. But you can only trade AFTER the RNS and you are no longer inside. In that instance its like the naked short selling that MMs do, they are not selling real shares, just promising by the time you settle and consolidate the shares will be correct.
You will probably find alot of those 1m delayed trades etc are forward sold or just being sold by the brokers, honestly nothing that unusual about them
The next way it happens here, before the placing happens, could be weeks in advance, IE as soon as FDA lifted the hold, people BORROWED shares, Interactive Brokers does this alot and lets clients borrow shares belonging to other clients. It does not go on otex and its pretty grey and hard to track. Someone can sell those borrowed shares, IE short, then when they take part in the placing the shares are added to their account and basically cancel out the borrowed stock. In these cases there should not be any trades printed ever, they were only sold the once and dont need to be bought back.
The Third way is where you just bet against the stock, PROBABLY spreadbet but could be CFDs as well, spreadex, IG and others let you do it. You dont SELL shares you bet against the stock and the platform hedges by selling shares if necessary OR just does not buy if another client buys. Short enough this way and although less immediate the platform still sells and it still hurts the SP. You can push the SP down to make the placing much cheaper, hedging your own risk by taking part in the placing and selling your shares into any rise to keep it down as you close off your spread or CFD positions, taking a loss on the physical shares but increasing profits on the Spread.
There are advantages to this last approach, as the shares you sell are not protected by an ISA etc you realise a capital gains LOSS if you sell at 1.9 having paid 2p HOWEVER you make that back and then some in the profits from the spreadbet.
ALL of these approaches are ILLEGAL if you do ANY trading or POSTING about the placing whilst your inside.
Glenn, I have to be honest, I KNEW it was coming but I still s4@7 myself and jumped, my deepest apologies, but I HAD to share...
Pedro, dont be so obtuse, Angle has nothing to do with Hemogenyx. I will be straight, Angle are not comparable to Hemogenyx they are a diagnostic company and even if they have had good results, potential revenue streams from diagnostics compared with treatments is just not on the same scale. So please dont try getting acute with your cross ramping. My reflex is to invest more in Hemo and wait for the flippers to sell. So my advice is to do a 180 degree, right back to their board as there is Zero Angle interest here, does not take a degree to spot which one has the most upside :-)
Wow, this one looks good! https://x.com/PicturesFoIder/status/1765141276771389586?s=20
New measures announced to encourages investments in UK stocks
Two measures have been announced to get more people and pension funds to invest un UK stocks.
"British ISA which will allow an additional £5,000 annual investment for investments in UK equity with all the tax advantages of other ISAs. This will be on top of the existing ISA allowances and ensure that British savers can benefit from the growth of the most promising UK businesses," Hunt says.
It will also force local authorities and defined contribution (DC) pension funds to disclose how much they have invested in UK shares.
UK pension funds currently invest a fraction (4%) of their assets in UK shares.
That placing and the weeks running up to it were a disgusting disaster, captain hindsight does NOT want to see a repeat. My hope is Vlad likewise is willing to look at what happened, reflect and resolve to never let it happen again.
It's a mute point now as company as used up most of its dilution, however go back pre IND approval. Imagine Vlad had approached some large investors and offered a placing, made them inside and offered at 3p to pay for phase 1 trials to close when FDA lifted the hold. When the FDA lift the hold RNS that plus details of placing.
There would have been ZERO opportunity for the shorters to come on shouting placing, people would have been VERY reluctant to short before CH lifted and the placing potentially could have been at a premium.
Would placees have sold into the rise???? PROBABLY. But the alternative is placing AFTER the news where shorters feel comfortable pushing down the sp and you have lost the big ticket item of IND approval.
The inside information in the placing was the placing itself, THAT is what they use to trade and short. If we know a placing is coming Because of positive developments and updates??? How can people short?
Stonk, investors can be made inside and provided inside information to allow them to decide if they want to take part in a placing. But considering what happens here? Where every great rns is followed by placing? What is the definition of insanity???
Haywain.... I hope your wrong.... rats fair enough, but not dogs!!!
Haywain, this was an extract of an email I sent to the company recently, its MY email so sharing nothing from the company here without permission. What I would say is my hope that this is NEVER needed and the company is able to licence HEMO-CAR-T for 100m up front after proving it works which IMO is very likely:
"For example, lets say your about to launch animal testing for CBR against Covid-19, we all know monkeys cost money as does a lvl3 facility, so in a situation like that, rather than dipping into the bank, approach the larger investors you can trust, make them inside, say your about to start these IND enabling studies and require a few million, raise at the closing or even a slight premium as much as they are willing. Then when the placing is closed RNS placing with update on what the money is for AND if you want some more fund extend a retail offer to existing share holders via brokers.
This approach:
Retail not forewarned so cannot short in advance
Easier to fix a placing price as no RNS prior causing instability/shorting opportunity
Market knows the funding is for positive developments
Company not forced to dip into bank for large expenditures meaning you never get into that vulnerable state again."
Basically what we have seen in recent years is placings AFTER news, its now taken as a given that it will happen off the back of any news and because of that there is no material benefit to doing AFTER the news lands in instead is an anchor preventing any sort of meaningful gain and only traders/shorters/forward sellers win.
So my suggestion is simple in future if they want to place? do it BEFORE news, give the insider investors that inside knowledge and let them pay a premium if they think the news is good enough and dont even go near the retail that tank the SP until AFTER it closes and offer them whats left.
I am interested on your thoughts on this approach, and if supported perhaps Vlad would be inclined to change his approach to funding. HOWEVER priority number one should be just to do away with placings and LICENCE!!!
Mjng, just saw your post, sorry! But 100% agree with everything you wrote.